Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary?

被引:32
作者
Elias, N
Tanabe, KK
Sober, AJ
Gadd, MA
Mihm, MC
Goodspeed, B
Cosimi, AB
机构
[1] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
关键词
D O I
10.1001/archsurg.139.4.400
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hypothesis: Completion lymph node dissection (CLND) has usually been recommended after metastatic disease is identified in the sentinel lymph node (SLN) biopsy to eradicate further metastases in nonsentinel nodes. We hypothesized that patients with negative lymph nodes included in the initial SLN specimen have low risk of metastases in the residual draining basin and may not require CLND. Design: Chart review. Setting: University-affiliated tertiary care referral center. Patients: Between January 1, 1997, and May 31, 2003, 506 consecutive patients underwent SLN biopsy for staging of primary cutaneous melanoma. Intervention: The SLN biopsy identified 87 patients (17.2%) with metastatic melanoma, of whom 80 underwent CLND. Results: In 28 patients, all SLNs were found to contain metastatic melanoma. Seven (25%) of these patients had additional metastases identified in the CLND specimen. In 52 patients, 1 or more SLNs did not contain metastatic melanoma. Five (10%) of these patients had additional metastases in the CLND specimen (P = .02). Conclusions: Although no evidence of metastatic melanoma was found on CLND in most patients in whom negative nodes had been removed with positive SLNs at the initial biopsy, 10% of these patients did have further metastases. This subgroup of patients (positive SLNs and negative nodes in the SLN biopsy specimen) is at significantly lower risk for further metastasis, but CLND cannot be safely omitted even for these patients.
引用
收藏
页码:400 / 404
页数:5
相关论文
共 27 条
[21]   INEFFICACY OF IMMEDIATE NODE DISSECTION IN STAGE-1 MELANOMA OF LIMBS [J].
VERONESI, U ;
ADAMUS, J ;
BANDIERA, DC ;
BRENNHOVD, IO ;
CACERES, E ;
CASCINELLI, N ;
CLAUDIO, F ;
IKONOPISOV, RL ;
JAVORSKJ, VV ;
KIROV, S ;
KULAKOWSKI, A ;
LACOUR, J ;
LEJEUNE, F ;
MECHL, Z ;
MORABITO, A ;
RODE, I ;
SERGEEV, S ;
VANSLOOTEN, E ;
SZCZYGIEL, K ;
TRAPEZNIKOV, NN ;
WAGNER, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (12) :627-630
[22]  
Wagner JD, 2000, CANCER-AM CANCER SOC, V89, P453, DOI 10.1002/1097-0142(20000715)89:2<453::AID-CNCR34>3.0.CO
[23]  
2-V
[24]   Parotid selective lymphadenectomy in malignant melanoma [J].
Wells, KE ;
Stadelmann, WK ;
Rapaport, DP ;
Hamlin, R ;
Cruse, CW ;
Reintgen, D .
ANNALS OF PLASTIC SURGERY, 1999, 43 (01) :1-6
[25]   Sentinel lymph node biopsy in melanoma of the head and neck [J].
Wells, KE ;
Rapaport, DP ;
Cruse, CW ;
Payne, W ;
Albertini, J ;
Berman, C ;
Lyman, GH ;
Reintgen, DS .
PLASTIC AND RECONSTRUCTIVE SURGERY, 1997, 100 (03) :591-594
[26]  
Yu LL, 1999, CANCER, V86, P617, DOI 10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.3.CO
[27]  
2-J